title: Docetaxel for advanced prostate cancer: how early to start?
authors.affiliation: DUMC Box 103861, Duke Cancer Institute, Divisions of Medical Oncology and Urology, Duke University, Durham, NC 27710, USA. Electronic address: andrew.armstrong@duke.edu.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Armstrong
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen